Final inline filtration for intravenous infusions: A prospective hospital study

Author:

Allcutt D A1,Lort D1,McCollum C N1

Affiliation:

1. University Department of Surgery, Queen Elizabeth Hospital, Birmingham B15 2TH

Abstract

Abstract Phlebitis is the most common complication of intravenous therapy affecting more than 50 per cent of infusions. Particles in or added to infusions have been implicated, hence a filter with pore size of 0.2/ μm containing both hydrophobic and hydrophilic elements (Pall Biomedical) has been evaluated. All infusions of likely duration greater than 48 h, set up in a 2-month period at this hospital, were randomized to filter or identical dummy. The endpoints and statistical power of the study were determined at the outset. Of the 226 infusions randomized, 32 failed within 24 h and were excluded leaving 194 of whom 93 had dummy and 101 filter. Only 38 infusions with dummy survived until no longer required compared to 63 infusions with filter (χ2 = 7.68, P < 0.01). Analysed by life table, the trend for filtered infusions to survive longer failed to achieve statistical significance, but inline filtration prolonged the phlebitis-free survival of infusions (P < 0.01). These benefits were most marked in the 49 infusions where antibiotics were administered via the drip site. Inline filtration delays the onset of phlebitis, thus more infusions survive until they are no longer required. This effect is not sufficiently strong to institute an overall hospital policy but filters may be indicated in patients requiring intravenous antibiotics.

Publisher

Oxford University Press (OUP)

Subject

Surgery

Reference15 articles.

1. Inline final filtration—a method of minimising contamination in intravenous therapy;Ryan;Bull. Parent. Drug Assoc.,1973

2. Infusion thrombophlebitis;Brown;Br. J. Clin. Pract.,1970

3. A study of particulate matter in IV infusion fluids;Davis;Am. J. Hosp. Pharm.,1970

4. Clinical significance of particulate matter: a review of the literature;Turco;Hosp. Pharm.,1973

5. Particulate matter in commercial antibiotic injectable products;Masuda;Am. J. Hosp. Pharm.,1973

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3